S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
ASX:PBT

Prana Biotechnology Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive PBT News and Ratings via Email

Sign-up to receive the latest news and ratings for Prana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.


About Prana Biotechnology

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Prana Biotechnology (ASX:PBT) Frequently Asked Questions

What stocks does MarketBeat like better than Prana Biotechnology?

Wall Street analysts have given Prana Biotechnology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prana Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Prana Biotechnology's earnings last quarter?

Prana Biotechnology Limited (ASX:PBT) announced its earnings results on Thursday, February, 28th. The biotechnology company reported ($0.01) earnings per share for the quarter.
View Prana Biotechnology's earnings history
.

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the following people:
  • Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)
  • Ms. Kathryn Andrews, Chief Financial Officer (Age 52)
  • Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)
  • Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum M.D., Chief Medical Advisor

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the ASX under the ticker symbol "PBT."

How much money does Prana Biotechnology make?

Prana Biotechnology has a market capitalization of $0.00.

How many employees does Prana Biotechnology have?

Prana Biotechnology employs 14 workers across the globe.

What is Prana Biotechnology's official website?

The official website for Prana Biotechnology is pranabio.com.

Where are Prana Biotechnology's headquarters?

Prana Biotechnology is headquartered at PO Box 655, MELBOURNE, VIC 3053, Australia.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is PO Box 655, MELBOURNE, VIC 3053, Australia. The biotechnology company can be reached via phone at +61-3-93494906.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.